Day One Biopharmaceuticals, INC. (DAWN) — 8-K Filings

All 8-K filings from Day One Biopharmaceuticals, INC.. Browse 18 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (18)

Day One Bio Files 8-K: Asset Disposition, Control Changes — Apr 23, 2026 Risk: medium
Day One Biopharmaceuticals, Inc. filed an 8-K on April 23, 2026, reporting several material events. These include the termination of a material definitive agree
Day One Biopharma Files 8-K — Nov 24, 2025 Risk: low
On November 24, 2025, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial
Day One Biopharmaceuticals Enters Material Definitive Agreement — Nov 13, 2025 Risk: medium
On November 12, 2025, Day One Biopharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal ex
Day One Biopharma Reports Director Changes and Executive Compensation Updates — Oct 10, 2025 Risk: medium
On October 7, 2025, Day One Biopharmaceuticals, Inc. reported changes in its board of directors and executive compensation arrangements. Specifically, the compa
Day One Biopharma Files 8-K on Shareholder Vote Matters — Jun 3, 2025 Risk: low
On June 2, 2025, Day One Biopharmaceuticals, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing, made on
Day One Biopharma Files 8-K — Jan 13, 2025 Risk: low
On January 13, 2025, Day One Biopharmaceuticals, Inc. filed a Form 8-K to report its current status. The filing confirms the company's principal executive offic
Day One Biopharma Elects New Directors, Adjusts Officer Compensation — Nov 20, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. announced on November 20, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the co
Day One Biopharma Files 8-K: Material Agreement & Equity Sales — Jul 30, 2024 Risk: medium
On July 30, 2024, Day One Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securit
Day One Biopharma Files 8-K on Financials — Jul 30, 2024 Risk: low
On July 30, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report detailing the results of operations and financial condition. The filing also included Reg
Day One Biopharma Files 8-K: Material Agreement & Equity Sales — Jul 25, 2024 Risk: medium
On July 23, 2024, Day One Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securit
Day One Biopharmaceuticals Files 8-K — Jun 18, 2024 Risk: low
On June 17, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and registered sec
Day One Biopharma Files 8-K — Jun 12, 2024 Risk: low
On June 12, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2000 Sierr
Shionogi Acquires Day One Biopharmaceuticals — May 30, 2024 Risk: low
On May 29, 2024, Day One Biopharmaceuticals, Inc. announced the completion of its acquisition by Shionogi & Co., Ltd. The transaction was completed following th
Day One Biopharm Files 8-K on Shareholder Vote — May 24, 2024 Risk: low
Day One Biopharmaceuticals, Inc. filed an 8-K on May 24, 2024, reporting on a matter submitted to a vote of its security holders on May 23, 2024. The filing doe
8-K Filing — Apr 24, 2024
Day One Biopharmaceuticals Files 8-K Report — Mar 7, 2024 Risk: low
On March 4, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No
Day One Bio Files 8-K on Officer Changes, Reg FD Disclosure — Jan 17, 2024
Day One Biopharmaceuticals, Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024. This filing indicates changes related t
Day One Bio Files 8-K, Confirms Nasdaq Listing Under DAWN — Jan 8, 2024
Day One Biopharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly trade

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX